Page 36 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY

ADULT-ONSET ASTHMA – PREDICTORS OF CLINICAL COURSE AND SEVERITY
41. Al-Samri MT, Benede A, Prefontaine D, Olivenstein R, Lemiere C, Nair P, et al. Variability of sputum in ammatory cells in asthma c pa ents receiving cor costeroid therapy: A prospec ve study using mul ple samples. J Allergy Clin Immunol 2010; 125:1161-3 e4.
42. van Veen IH, ten Brinke A, Gauw SA, Sterk PJ, Rabe KF, Bel EH. Consistency of sputum eosinophilia in di cult-to-treat asthma: A 5-year follow-up study. Journal of Allergy and Clinical Immunology 2009; 124:615-7.
43. Newby C, Agbe le J, Hargadon B, Monteiro W, Green R, Pavord I, et al. Lung func on decline and variable airway in ammatory pa ern: longitudinal analysis of severe asthma. J Allergy Clin Immunol 2014; 134:287-94.
44. ten Brinke A, van Dissel JT, Sterk PJ, Zwinderman AH, Rabe KF, Bel EH. Persistent air ow limita on in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infec on. Journal of Allergy and Clinical Immunology 2001; 107:449-54.
45. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent air ow limita on in severe or di cult-to-treat asthma: insights from the TENOR study. Chest 2007; 132:1882-9.
46. Perret JL, Dharmage SC, Matheson MC, Johns DP, Gurrin LC, Burgess JA, et al. The interplay between the e ects of life me asthma, smoking, and atopy on xed air ow obstruc on in middle age. Am J Respir Crit Care Med 2013; 187:42-8.
47. Anees W, Moore VC, Burge PS. FEV1 decline in occupa onal asthma. Thorax 2006; 61:751-5.
48. Lin FJ, Dimich-Ward H, Chan-Yeung M. Longitudinal decline in lung func on in pa ents with occupa onal asthma due to western red cedar. Occup Environ Med 1996; 53:753-6.
49. Talini D, Novelli F, Bacci E, Bartoli M, Cianche S, Costa F, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupa onal asthma: results of an observa onal study. BMJ Open 2015; 5:e005748.
50. Perfe L, Car er A, Ghezzo H, Gautrin D, Malo JL. Follow-up of occupa onal asthma a er removal from or diminu on of exposure to the responsible agent: relevance of the length of the interval from cessa on of exposure. Chest 1998; 114:398-403.
51. Padoan M, Pozzato V, Simoni M, Zedda L, Milan G, Bononi I, et al. Long-term follow-up of toluene diisocyanate-induced asthma. European Respiratory Journal 2003; 21:637-40.
52. Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116:990-5.
53. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Interna onal ERS/ATS guidelines on de ni on, evalua on and treatment of severe asthma. Eur Respir J 2014; 43:343-73.
54. Global Strategy for Asthma Management and Preven on 2014 (update). 2014.] Available from h p:// www.ginasthma.org/local/uploads/ les/GINA_Pocket_2014_Jun11.pdf.
55. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and de ni on of severe refractory asthma: an interna onal consensus statement from the Innova ve Medicine Ini a ve (IMI). Thorax 2011; 66:910-7.
56. Juniper EF, Bousquet J, Abetz L, Bateman ED. Iden fying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Ques onnaire. Respir.Med. 2006; 100:616-21.
57. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An o cial American Thoracic Society/European Respiratory Society statement: asthma control and exacerba ons: standar- dizing endpoints for clinical asthma trials and clinical prac ce. Am J Respir Crit Care Med 2009; 180:59-99.
58. Wu TJ, Chen BY, Lee YL, Hsiue TR, Wu CF, Guo YL. Di erent Severity and Severity Predictors in Early-Onset and Late-Onset Asthma: A Taiwanese Popula on-Based Study. Respira on 2015.
34